Objective: While oxytocin has been identified as having therapeutic properties for schizophrenia, the emerging evidence has been mixed which has resulted in meta-analytic reviews. We identified several errors in one such meta-analysis. Here, we highlight these errors, demonstrate the conclusions were incorrect, and state the importance of this report.
Methods: We reproduced the methods of Gumley, Braehler, and Macbeth (), including: outcomes (positive, negative, and total symptoms, as well as general psychopathology) and meta-analytic estimates for fixed and random effect models.
Results: Whereas Gumley, Braehler, and Macbeth () reported oxytocin had significant effects on three of four outcomes, we show that all effects were non-significant.
Conclusions: Based on these null results, we hope this report encourages a re-evaluation of intranasal oxytocin as a treatment for schizophrenia.
Keywords: intranasal; meta-analysis; oxytocin; schizophrenia.
© 2017 The British Psychological Society.